Grey Matters Health Inc (AGNPF)

[Money $hot]

Algernon Pharmaceuticals Intellectual Property – Drug Program

Annual Information Form

For The Financial Year Ended August 31, 2018

April 11, 2019

Page(s) 27 & 28

The Company’s major asset revolves around a number of provisional patents that have been filed protecting its key scientific discoveries. Since all of Algernon’s lead compounds are already genericized, all of the original composition of matter patents have expired. Prior to the selection of the initial 11 drug
compounds that were selected for screening, an initial intellectual property search was conducted in order to gain insight on the intellectual property landscape for these compounds. Once the initial in vivo animal research studies were concluded for each disease, searches were conducted by two independent leading Canadian trade mark law firms confirming the suitability for filing new method of use patents. Once the search was completed, method of use provisional patents were filed for all of the active compounds from each of the research studies.

Where Algernon deemed it necessary, and based on intellectual property searches for NCEs, the Company has also taken each lead compound and has additionally filed a markush structure patent. This approach will minimize the risk of a third party trying to make small structural changes to Algernon’s lead compounds and filing new composition of matter patents. This strategy was designed to help convince a potential competitors that exploring a partnership or licensing agreement with the Company would be a far more productive that trying to compete by developing a new NCE program for derivatives developed around the core structure of our lead compounds.

If the Company begins to synthesize any of their lead compounds for a phase III trial, some modifications to the drugs current formula may be made which could provide an opportunity to file additional formulation patents.

https://webfiles.thecse.com/sedar_filings/00037722/1904160953176150.pdf

/////AMG